Health Care

Top Glove champions community sport at the Lightning Cup, boosting its CSR image while navigating tough healthcare supply‑chain and market pressures.

Unicycive Therapeutics leads the fight against hyperphosphatemia in kidney disease with two breakthrough therapies, offering safer, more effective options for patients and investors alike.

Explore Anavex Life Sciences’ breakthrough in precision genetic medicine targeting rare neurological disorders and its growth potential in the biotech market.

Discover why Agenus Inc. stock jumped 100% after a $340M private placement, funding the high‑potential BOT + BAL Phase 3 trial for MSS colon cancer and sparking a $30 analyst target.

AbbVie’s July 2026 ex‑dividend and Skyrizi‑driven $300 target show a resilient dividend strategy amid a brief price dip, yet drug‑pricing policy shifts still shape future gains.

Discover how aTyr Pharma’s physiocrine‑based biotech innovations could transform healthcare, plus insights into its market performance and future prospects.

Avant Brands Inc. faces a tough road ahead: handcrafted Canadian cannabis quality clashes with a negative P/E and volatile stock, raising key questions about strategy and profitability.

Discover why VERADERMICS INC’s stock volatility, negative P/E, and opaque operations are raising red flags for investors in the fast‑moving healthcare sector.

Blue Sail Medical surges as China’s medical‑device boom heats up: policy lift, earnings rebound, and ETF rally signal a new high‑growth era for the firm.

Discover how Bayer’s Supreme Court win reshapes its legal, market, and credit outlook—uncover risks, rally potential, and future growth strategies.